Sarah Popham is the Vice President of Regulatory at Latigo Biotherapeutics, bringing more than 25 years of drug development experience. She has held key leadership roles in clinical development and regulatory affairs across the biopharmaceutical industry, demonstrating a strong track record of delivering results and building effective teams. Sarah’s experience spans major biopharma companies such as GlaxoSmithKline, Genentech, and Amgen, as well as smaller firms like atai Life Sciences. Most recently, she played a pivotal role in establishing and leading Amgen’s Intercontinental region, managing regulatory activities across Canada, Latin America, the Middle East, Africa, and Turkey, and navigating regulatory complexities in more than 40 countries. Sarah has contributed to the approval of many marketed products and has worked extensively with commercial teams on later-stage product development strategies. Her expertise encompasses multiple modalities and therapeutic areas, including Oncology, CNS, Biosimilars, and psychedelics. Sarah holds a BSc Hons in Biomedical Sciences from the University of Bradford, UK.